Weight loss

LeAnn Boyd, Liviniti CEO, Delivers GLP-1 Insights at HPI Innovations Conference

Retrieved on: 
星期四, 四月 25, 2024
Pharmacy, Health, PBM, Business development, HPI, Weight loss, Conference, Obesity, Senior, Leanne, Overalls

Panel to discuss impact of popular weight-loss drugs on the self-funded employer market

Key Points: 
  • Natchitoches, Louisiana--(Newsfile Corp. - April 25, 2024) - LeAnn Boyd, Liviniti CEO, will join national healthcare leaders in a panel discussion at the HPI Innovations Self-Funding Conference on Tuesday, April 30 in Boston.
  • Hugh Gallagher, Senior Vice President, Leaf Health, will moderate the GLP-1 panel discussion titled: How a Side Effect Turned into a Selling Point for Pharma.
  • Known for breakthrough innovations in the pharmacy benefit management space, Liviniti was the first PBM to announce a collaborative weight-loss program with Noom for Work.
  • LeAnn will add her insights to the discussion as the panel reviews the origination of GLP-1s, their impact on overall health and weight loss, and their impact on the self-funded employer market.

Nutritional Biochemist Franco Cavaleri Will Speak at 2024 White Label World Expo, Sharing Insights on Health Science Innovation

Retrieved on: 
星期一, 四月 15, 2024
Science, Pain, Experiment, News, Las Vegas Convention Center, Biologic, Health, Cognition, PubMed, Entrepreneurship, Weight loss, Research, Pharmacology, Withania somnifera, Ebook, White label, Curcumin, Video game

The former Mr. North America IFBB Champion is a world-renowned biomedical researcher, author, entrepreneur and innovator.

Key Points: 
  • "I am thrilled to participate in the White Label World Expo and engage with fellow innovators and industry leaders," Cavaleri said.
  • Cavaleri's speech at the White Label World Expo is titled "Revolutionizing Health: Science, Innovation, and Entrepreneurship" and promises to be a highlight, offering attendees invaluable insights into the dynamic intersection of science and entrepreneurship in health and wellness.
  • The White Label World Expo is a huge expo event that redefines the landscape of online retailing and entrepreneurship.
  • "I'm thrilled to be speaking at the White Label World Expo, where industry leaders converge to explore the forefront of innovation," Cavaleri said.

Ibogaine By David Dardashti Acknowledges Importance of Body Image in Addiction and Mental Health Recovery

Retrieved on: 
星期五, 四月 26, 2024
Health, Body image, Weight loss, Mental health

Body image is an issue that has long been linked to addiction and mental health issues.

Key Points: 
  • Body image is an issue that has long been linked to addiction and mental health issues.
  • Preoccupation with a person’s appearance can have a substantial impact on a person’s ongoing struggles with addiction and mental health.
  • David Dardashti, founder of Ibogaine By David Dardashti, expressed his views on the significance of body image in the healing process, “We are seeing more and more individuals who have an unhealthy preoccupation with their body image.
  • Ibogaine By David Dardashti is actively encouraging individuals to focus on self-love and stop worrying about body image.

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

Retrieved on: 
星期四, 四月 25, 2024
Patient, Obesity, Annual general meeting, Weight loss, AACE

MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two late-breaking abstract presentations at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting, taking place May 9-11, 2024 in New Orleans, LA.

Key Points: 
  • MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two late-breaking abstract presentations at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting, taking place May 9-11, 2024 in New Orleans, LA.
  • Potential to Optimize Weight Loss with Enobosarm: Augment Reduction of Fat Mass while Preserving Muscle in Older Patients with Obesity
    Additional information on the meeting can be found on the AACE website: https://pro.aace.com/

Aphaia Pharma Provides Enrollment and Protocol Update for Phase 2 Trial in Individuals with Obesity

Retrieved on: 
星期四, 四月 25, 2024
FDA, Safety, Food, Weight loss, Cohort, Obesity, Patient, DSM-IV codes, Metabolism, SAN, Pharmaceutical industry

The new protocol will include four additional cohorts, which will be dosed with either 6g (APHD-006) or 8g (APHD-008) of Aphaia’s formulation or their respective placebos twice per day.

Key Points: 
  • The new protocol will include four additional cohorts, which will be dosed with either 6g (APHD-006) or 8g (APHD-008) of Aphaia’s formulation or their respective placebos twice per day.
  • With the expansion of the protocol, Aphaia aims to leverage the beneficial effects of circadian timing, which are known to improve metabolic diseases and weight control.
  • The Phase 2 trial ( NCT05385978 ) is a randomized, double-blind, placebo-controlled, proof-of-concept study assessing the safety and efficacy of Aphaia’s oral glucose formulation in adults with obesity.
  • The study will also evaluate exploratory secondary endpoints, which are hallmarks of multiple metabolic diseases closely associated with obesity.

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

Retrieved on: 
星期二, 四月 23, 2024
Sequence, Small RNA, RNA editing, Potency, Durability, Health, ...Continued, RNA, MD, Doctor of Philosophy, Weight loss, IND, CNS, Obesity, Oligonucleotide, GSK, Patient, Medicinal chemistry, MBA, Liu Wei, Clinical trial, Pharmaceutical industry

CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today provided an update on its best-in-class small interfering RNA (siRNA) and RNA editing platform capabilities.

Key Points: 
  • As part of Wave’s ongoing collaboration with GSK, GSK has selected its first two programs to advance to development candidates following achievement of target validation.
  • GSK will provide an aggregate initiation payment of $12 million to Wave for these two oligonucleotide programs.
  • Under the agreement, GSK can advance up to eight programs leveraging Wave’s PRISM™ platform and multiple RNA-targeting modalities (RNA editing, splicing, siRNA, and antisense) with target validation work ongoing across multiple therapy areas.
  • Beyond these programs, our collaboration is focusing on all Wave modalities, including RNA editing.

Dalrada Financial Corporation’s Wholly-Owned Subsidiary, Genefic, Inc. Announces New Telemedicine Services, Enters Booming Weight Loss Drug Market

Retrieved on: 
星期二, 四月 23, 2024
Weight loss, SAN, Health, OTCQB, Dietary supplement

SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada,” “the Company”), announced today that its wholly-owned healthcare subsidiary, Genefic, Inc. (“Genefic”), has added a telemedicine service to its specialty pharmacy, allowing Genefic to efficiently offer clients direct access to its pharmaceuticals, including access to Genefic’s own weight loss drug, as the subsidiary enters the world’s booming weight loss drug market.

Key Points: 
  • SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Dalrada Financial Corporation (OTCQB: DFCO , “Dalrada,” “the Company”), announced today that its wholly-owned healthcare subsidiary, Genefic, Inc. (“Genefic”), has added a telemedicine service to its specialty pharmacy , allowing Genefic to efficiently offer clients direct access to its pharmaceuticals, including access to Genefic’s own weight loss drug, as the subsidiary enters the world’s booming weight loss drug market.
  • With the global weight loss drug market currently worth approximately $6 billion and projected to reach nearly $100 billion by the end of the decade, the overall popularity of weight loss drugs is driving a meteoric rise in market value.
  • Additionally, the expected compound annual growth rate (CAGR) of 45.7% suggests that 2024 is ideal for Genefic to enter the weight loss drug market, according to the subsidiary’s president, Dan Riley.
  • Working within the weight loss drug market will present us with a wider reach than ever before while driving significant revenue.”

VIVUS Announces it will Provide Telehealth to Patients through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth

Retrieved on: 
星期一, 四月 22, 2024
Mortality, FDA, Patient, Pharmacy, Risk, Food, Hunger, Weight loss, Partnership, Obesity, Exercise, Dyslipidemia, Type 2 diabetes, Hypertension, Cardiovascular disease, Phentermine, Prevalence, Ageing

CAMPBELL, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced it has entered into a strategic partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company. The program, titled “VIVUS Engage,” will establish a robust online telemedicine platform for the distribution of QSYMIA® (phentermine and topiramate extended-release capsules CIV), the leading non-injectable branded weight loss medication in the U.S. for adults.

Key Points: 
  • Under the terms of the agreement, UpScript LLC will make QSYMIA available to patients through its proprietary Telehealth Platform.
  • With over 20 years of experience and more than one million patients served, UpScriptHealth specializes in creating effective web-based campaigns for pharmaceutical companies.
  • For patients actively seeking online support and solutions, UpScriptHealth offers a fast and convenient option.
  • Combined with a healthy diet and exercise, it has been proven to help patients lose weight and maintain weight loss.

Bestqool proves the effectiveness and safety of its red light therapy device with a professional third-party Report

Retrieved on: 
星期三, 四月 17, 2024
Physical, Enzyme, Cell, RLT, Safety, Skin, Tissue, Bacteria, NASA, Weight loss, System, Carbon, Plant, Mitochondrion, Oxygen, Phagocytosis, Vasodilation, Medicine, Virus, Nutrient, Regeneration, Food preservation

Bestqool , a leading manufacturer in the industry of red light therapy, offers lifestyle game-changing devices that prioritize safety, efficacy, and user comfort.

Key Points: 
  • Bestqool , a leading manufacturer in the industry of red light therapy, offers lifestyle game-changing devices that prioritize safety, efficacy, and user comfort.
  • The utilization of red light therapy in well-being has its roots dating back to ancient Greek times.
  • Unlike ultraviolet light, red light is harmless to the skin and does not tan or cause dark spots to the skin.
  • One of the crucial factors that the reader needs to pay attention to when buying red light therapy is RLT device irradiance.

Solera Health Expands its Curated Network to Help Payers and Employers Address High-Cost Cardiometabolic Disease

Retrieved on: 
星期二, 四月 16, 2024
Mortality, Genetics, International Journal of Obesity, Diabetes, Weight loss, Obesity, Solera, Patient, Movement, Hypertension, Cardiovascular disease, Longevity, Anxiety, Sleep, HALO, Disease, Pharmaceutical industry

The additional solutions enable payers and employers to address high-cost conditions associated with cardiometabolic health – integrating several proven, industry-leading digital health partners.

Key Points: 
  • The additional solutions enable payers and employers to address high-cost conditions associated with cardiometabolic health – integrating several proven, industry-leading digital health partners.
  • New solutions enhance Solera’s ability to impact hypertension, high cholesterol, diabetes prevention and weight management – and include Ciba Health, Digbi Health and Wondr Health.
  • Diabetes and cardiovascular disease are among the most expensive and prevalent diseases in the U.S., affecting over 121 million Americans.
  • "Cardiometabolic conditions remain a leading cause of preventable morbidity and mortality while accounting for over 30% of healthcare costs in the United States alone,” said Dr. Byron Crowe, Chief Medical Officer at Solera Health.